Gell Pharmaceuticals gets $2.5 mil. to develop cocaine addiction treatments from the Abell Foundation.
GELL PHARMACEUTICALS GETS $2.5 MIL. TO DEVELOP COCAINE ADDICTION TREATMENTS from the Abell Foundation, a Baltimore philanthropic organization affiliated with the family that publishes the Baltimore Sun newspapers. The $2.5 mil. will provide start-up funds for GELL, which is 20% owned by Baltimore-based Guilford Pharmaceuticals and 80% owned by Abell. GELL will attempt to develop a compound to treat cocaine addiction based on research conducted at Johns Hopkins University and the National Institute on Drug Abuse of the National Institutes of Health.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth